PMID- 36825605
OWN - NLM
STAT- MEDLINE
DCOM- 20230510
LR  - 20230511
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 8
DP  - 2023 Apr
TI  - The predictive value of lymphocyte to monocyte ratio for overall survival in 
      cholangiocarcinoma patients with hepatic resection.
PG  - 9482-9495
LID - 10.1002/cam4.5712 [doi]
AB  - BACKGROUND: There is considerable heterogeneity in clinical behavior and survival 
      outcomes in patients with cholangiocarcinoma (CCA), and the prognosis of CCA 
      patients is poor. We proposed lymphocyte to monocyte ratio (LMR) as a novel 
      prognostic element for CCA patients with hepatic resection in present study. 
      METHODS: By retrospectively analyzing the clinical data of 145 CCA patients with 
      hepatic resection, we determined the optimal LMR cutoff value according to the 
      receiver operating characteristic (ROC). We comparatively analyzed the clinical 
      features of CAA patients between low LMR group and high LMR group, mainly 
      including overall survival (OS) analysis by using the Kaplan-Meier method, 
      univariate and multivariate Cox regression. RESULTS: We found there was a longer 
      OS in CCA patients of the high LMR group than the low LMR group. The total median 
      OS of cholangiocarcinoma patients were 13.6 months, and the OS of low LMR group 
      was markedly lower than the high LMR group. The 1-year, 3-year, and 5-year OS of 
      high LMR group were respectively 62.9%, 32.4%, and 16.4%, and were significantly 
      higher the cholangiocarcinoma patients of low LMR group (40.2%, 16.4%, and 0%). 
      Multivariate regression analyses showed that preoperative cholangitis, elevated 
      CEA level and nerve invasion were risk factors for the OS of cholangiocarcinoma 
      patients, while the high LMR level and postoperative treatment were protective 
      factors for the OS of cholangiocarcinoma patients. CONCLUSIONS: Preoperative LMR 
      was a vital prognostic factor to predict the prognosis of CCA patients with 
      hepatic resection and provided additional prognostic value beyond standard 
      clinicopathological parameters.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Lv, Minghe
AU  - Lv M
AUID- ORCID: 0000-0001-9342-773X
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology Shanghai Medical College, Fudan University, Shanghai, 
      China.
AD  - Shanghai Clinical Research Center for Radiotherapy Oncology Shanghai Key 
      Laboratory of Radiation Oncology, Shanghai, China.
FAU - Wang, Kun
AU  - Wang K
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology Shanghai Medical College, Fudan University, Shanghai, 
      China.
AD  - Shanghai Clinical Research Center for Radiotherapy Oncology Shanghai Key 
      Laboratory of Radiation Oncology, Shanghai, China.
FAU - Zhang, Zhiyuan
AU  - Zhang Z
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology Shanghai Medical College, Fudan University, Shanghai, 
      China.
AD  - Shanghai Clinical Research Center for Radiotherapy Oncology Shanghai Key 
      Laboratory of Radiation Oncology, Shanghai, China.
FAU - Zhang, Zhen
AU  - Zhang Z
AUID- ORCID: 0000-0001-6426-5364
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology Shanghai Medical College, Fudan University, Shanghai, 
      China.
AD  - Shanghai Clinical Research Center for Radiotherapy Oncology Shanghai Key 
      Laboratory of Radiation Oncology, Shanghai, China.
FAU - Wan, Juefeng
AU  - Wan J
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology Shanghai Medical College, Fudan University, Shanghai, 
      China.
AD  - Shanghai Clinical Research Center for Radiotherapy Oncology Shanghai Key 
      Laboratory of Radiation Oncology, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230224
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Humans
MH  - Monocytes
MH  - Retrospective Studies
MH  - Lymphocytes/pathology
MH  - Prognosis
MH  - *Cholangiocarcinoma/surgery/pathology
MH  - *Bile Duct Neoplasms/surgery/pathology
MH  - Bile Ducts, Intrahepatic
PMC - PMC10166960
OTO - NOTNLM
OT  - LMR
OT  - cholangiocarcinoma
OT  - lymphocyte
OT  - monocyte
OT  - overall survival
COIS- The authors declare that they have no competing interests.
EDAT- 2023/02/25 06:00
MHDA- 2023/05/10 06:42
PMCR- 2023/02/24
CRDT- 2023/02/24 06:13
PHST- 2022/12/20 00:00 [revised]
PHST- 2022/05/13 00:00 [received]
PHST- 2023/02/08 00:00 [accepted]
PHST- 2023/05/10 06:42 [medline]
PHST- 2023/02/25 06:00 [pubmed]
PHST- 2023/02/24 06:13 [entrez]
PHST- 2023/02/24 00:00 [pmc-release]
AID - CAM45712 [pii]
AID - 10.1002/cam4.5712 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Apr;12(8):9482-9495. doi: 10.1002/cam4.5712. Epub 2023 Feb 24.